An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging

被引:15
|
作者
Wanet, Marie [1 ]
Delor, Antoine [2 ]
Hanin, Francois-Xavier [3 ]
Ghaye, Benoit [4 ]
Van Maanen, Aline [5 ]
Remouchamps, Vincent [6 ]
Clermont, Christian [6 ]
Goossens, Samuel [1 ]
Lee, John Aldo [1 ]
Janssens, Guillaume [1 ]
Bol, Anne [1 ]
Geets, Xavier [1 ]
机构
[1] Catholic Univ Louvain, Inst Rech Expt & Clin, Ctr Mol Imaging Radiotherapy & Oncol MIRO, Ave Hippocrate,54 Bte B1-54-07, B-1200 Brussels, Belgium
[2] Clin Univ St Luc, Dept Radiat Oncol, B-1200 Brussels, Belgium
[3] Clin Univ St Luc, Dept Nucl Med, B-1200 Brussels, Belgium
[4] Clin Univ St Luc, Dept Radiol, B-1200 Brussels, Belgium
[5] Clin Univ St Luc, Stat Support Unit, Canc Ctr, B-1200 Brussels, Belgium
[6] CHU UCL Namur, Dept Radiat Oncol, Clin & Maternite St Elisabeth Namur, B-5000 Namur, Belgium
关键词
Non-small cell lung cancer; Dose escalation; FDG-PET imaging; Intensity modulated radiotherapy; Toxicity; 3-DIMENSIONAL CONFORMAL RADIOTHERAPY; ELECTIVE NODAL IRRADIATION; NORMAL TISSUE CONSTRAINTS; THERAPY ONCOLOGY GROUP; PHASE-II; CONCURRENT CHEMORADIATION; THORACIC RADIOTHERAPY; RESPONSE EVALUATION; NSCLC PATIENTS; SOLID TUMORS;
D O I
10.1007/s00066-017-1168-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Aim The aim of the study was to assess the feasibility of an individualized 18F fluorodeoxyglucose positron emission tomography (FDG-PET)-guided dose escalation boost in non-small cell lung cancer (NSCLC) patients and to assess its impact on local tumor control and toxicity. Patients and methods total of 13 patients with stage II-III NSCLC were enrolled to receive a dose of 62.5 Gy in 25 fractions to the CT-based planning target volume (PTV; primary turmor and affected lymph nodes). The fraction dose was increased within the individual PET-based PTV (PTVPET) using intensity modulated radiotherapy (IMRT) with a simultaneous integrated boost (SIB) until the predefined organ-at-risk (OAR) threshold was reached. Tumor response was assessed during follow-up by means of repeat FDG-PET/computed tomography. Acute and late toxicity were recorded and classified according to the CTCAE criteria (Version 4.0). Local progression-free survival was determined using the Kaplan-Meier method. Results The average dose to PTVPET reached 89.17 Gy for peripheral and 75 Gy for central tumors. After a median follow-up period of 29 months, seven patients were still alive, while six had died (four due to distant progression, two due to grade 5 toxicity). Local progression was seen in two patients in association with further recurrences. One and 2-year local progression free survival rates were 76.9% and 52.8%, respectively. Three cases of acute grade 3 esophagitis were seen. Two patients with central tumors developed late toxicity and died due to severe hemoptysis. Conclusion hese results suggest that a non-uniform and individualized dose escalation based on FDG-PET in IMRT delivery is feasible. The doses reached were higher in patients with peripheral compared to central tumors. This strategy enables good local control to be achieved at acceptable toxicity rates. However, dose escalation in centrally located tumors with direct invasion of mediastinal organs must be performed with great caution in order to avoid severe late toxicity.
引用
收藏
页码:812 / 822
页数:11
相关论文
共 50 条
  • [1] An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imagingStudie zur individualisierten Bestrahlungsdosiseskalation bei nichtkleinzelligem Lungenkarzinom basierend auf der FDG-PET-Bildgebung
    Marie Wanet
    Antoine Delor
    François-Xavier Hanin
    Benoît Ghaye
    Aline Van Maanen
    Vincent Remouchamps
    Christian Clermont
    Samuel Goossens
    John Aldo Lee
    Guillaume Janssens
    Anne Bol
    Xavier Geets
    Strahlentherapie und Onkologie, 2017, 193 : 812 - 822
  • [2] The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial)
    van Diessen, Judi
    De Ruysscher, Dirk
    Sonke, Jan-Jakob
    Damen, Eugene
    Sikorska, Karolina
    Reymen, Bart
    van Elmpt, Wouter
    Westman, Gunnar
    Persson, Gitte Fredberg
    Dieleman, Edith
    Bjorkestrand, Hedvig
    Faivre-Finn, Corinne
    Belderbos, Jose
    RADIOTHERAPY AND ONCOLOGY, 2019, 131 : 166 - 173
  • [3] The effect of FDG-PET on the stage distribution of non-small cell lung cancer
    Morgensztern, Daniel
    Goodgame, Boone
    Baggstrom, Maria Q.
    Govindan, Ramaswamy
    Gao, Feng
    JOURNAL OF THORACIC ONCOLOGY, 2008, 3 (02) : 135 - 139
  • [4] FDG-PET imaging in the management of non-small-cell lung cancer
    Salminen, E
    Mac Manus, M
    ANNALS OF ONCOLOGY, 2002, 13 (03) : 357 - 360
  • [5] Diagnostic and prognostic values of FDG-PET in patients with non-small cell lung cancer
    Abe, Koichiro
    Baba, Shingo
    Kaneko, Koichiro
    Isoda, Takuro
    Yabuuchi, Hidetake
    Sasaki, Masayuki
    Sakai, Shuji
    Yoshino, Ichiro
    Honda, Hiroshi
    CLINICAL IMAGING, 2009, 33 (02) : 90 - 95
  • [6] FDG-PET/CT imaging for tumor staging and definition of tumor volumes in radiation treatment planning in non-small cell lung cancer
    Zheng, Yuanda
    Sun, Xiaojiang
    Wang, Jian
    Zhang, Lingnan
    Di, Xiaoyun
    Xu, Yaping
    ONCOLOGY LETTERS, 2014, 7 (04) : 1015 - 1020
  • [7] Dose escalation for non-small cell lung cancer using conformal radiation therapy
    Robertson, JM
    TenHaken, RK
    Hazuka, MB
    Turrisi, AT
    Martel, MK
    Pu, AT
    Littles, JF
    Martinez, FJ
    Francis, IR
    Quint, LE
    Lichter, AS
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1997, 37 (05): : 1079 - 1085
  • [8] Usefulness of FDG-PET for early prediction of the response to gefitinib in non-small cell lung cancer
    Sunaga, Noriaki
    Oriuchi, Noboru
    Kaira, Kyoichi
    Yanagitani, Noriko
    Tomizawa, Yoshio
    Hisada, Takeshi
    Ishizuka, Tamotsu
    Endo, Keigo
    Mori, Masatomo
    LUNG CANCER, 2008, 59 (02) : 203 - 210
  • [9] The PET-boost randomised phase II dose-escalation trial in non-small cell lung cancer
    van Elmpt, Wouter
    De Ruysscher, Dirk
    van der Salm, Anke
    Lakeman, Annemarie
    van der Stoep, Judith
    Emans, Daisy
    Damen, Eugene
    Ollers, Michel
    Sonke, Jan-Jakob
    Belderbos, Jose
    RADIOTHERAPY AND ONCOLOGY, 2012, 104 (01) : 67 - 71
  • [10] FDG PET/CT as theranostic imaging in diagnosis of non-small cell lung cancer
    Kirienko, Margarita
    Gallivanone, Francesca
    Sollini, Martina
    Veronesi, Giulia
    Voulaz, Emanuele
    Antunovic, Lidjia
    Leonardi, Lorenzo
    Testanera, Giorgio
    Castiglioni, Isabella
    Chiti, Arturo
    FRONTIERS IN BIOSCIENCE-LANDMARK, 2017, 22 : 1713 - 1723